Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H34F3N7O4S |
Molecular Weight | 597.655 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]1([H])CC(C)(C)N(C1)c2c(ccc(n2)-n3ccc(n3)OCC(C)(C)C(F)(F)F)C(=NS(=O)(=O)c4cn(C)nc4C)O
InChI
InChIKey=MVRHVFSOIWFBTE-INIZCTEOSA-N
InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1
Molecular Formula | C26H34F3N7O4S |
Molecular Weight | 597.655 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 07:48:30 UTC 2021
by
admin
on
Sat Jun 26 07:48:30 UTC 2021
|
Record UNII |
RRN67GMB0V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
647618
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/18/2116
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB15444
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
134587348
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
2256951
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
11180
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
RRN67GMB0V
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
5372
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
2216712-66-0
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
Elexacaftor, Tezacaftor and Ivacaftor
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY | |||
|
C169935
Created by
admin on Sat Jun 26 07:48:31 UTC 2021 , Edited by admin on Sat Jun 26 07:48:31 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> ACTIVATOR |
modulator
|
||
|
EXCRETED UNCHANGED |
The concentrations of unchanged radiolabeled elexacaftor in urine were generally below the limit of quantification, indicating that renal clearance of elexacaftor is negligible in humans.
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TRANSPORTER -> SUBSTRATE |
Based on in vitro results
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||